📢 Calling fourth or fifth year #MedicalStudents looking to make an informed choice about their #Specialisation.
The #ESMOStudentCourse26 offers insights into #MedicalOncology, delivered by international experts.
📅 Apply by: 27 April 2026
🔗 https://ow.ly/UUir50YKhbK
#ADCs are reshaping breast oncology, alongside new questions on sequencing, biomarkers, and toxicity management. Explore this Ther Adv Med Oncol special collection, guest edited by Paolo Tarantino, MD, and Ilana Schlam, MD.
buff.ly/pZycpW5
#BreastCancer #ADCs #MedicalOncology #OncologyResearch
A new Special Collection in Ther Adv Med Oncol will explore emerging treatment strategies in HR+HER2‑ advanced #BreastCancer, a field marked by rapid therapeutic expansion and ongoing unmet need.
Submission deadline: 14 Dec 2026
buff.ly/Da8ENXI
#HRpositive #HER2negative #MedicalOncology
A real‑world retrospective study in Ther Adv Med Oncol examined the prevalence of HER2‑ultralow disease in HR+/HER2‑negative metastatic breast cancer and reported comparable first‑line chemotherapy outcomes to HER2‑low disease.
buff.ly/Q7JaadR
#BreastCancer #HER2 #MedicalOncology #RealWorldEvidence
Ther Adv Med Oncol announces an open call for a Special Collection on Advances in Clinical Care for Glioblastoma.
We welcome clinically actionable research across the care pathway, from diagnostics to patient‑centered outcomes.
buff.ly/8jRyYqj
#Glioblastoma #NeuroOncology #MedicalOncology
Antibody-drug conjugates in prostate cancer: current landscape and future directions
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#ADCs #cancertreatment #urology #medicaloncology #openaccess
Antibody-drug conjugates in breast oncology: new standards, emerging challenges, and future directions
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#ADCs #breastcancer #medicaloncology #cancertreatment #openaccess
A computer vision method to evaluate tumor-infiltrating lymphocytes and multiparametric modeling of neoadjuvant systemic therapy response in breast cancer
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#AI #cancertreatment #medicaloncology #openaccess
A dual‑center study in Ther Adv Med Oncol evaluated the Systemic Inflammation‑Nutrition Index (SINI) as a predictor of pathological response and relapse‑free survival in locally advanced #GIST treated with neoadjuvant imatinib.
buff.ly/fKecUtx
#Sarcoma #MedicalOncology #TargetedTherapy
Ther Adv Med Oncol announces an open call for a Special Collection on Modern Approaches to Patient Selection in Breast Cancer.
Submissions addressing biomarkers, computational tools, and integrated clinical strategies are welcome.
buff.ly/t6TEH5G
#BreastCancer #MedicalOncology #PrecisionOncology
Schematic overview of the findings of the publication by Suarez-Csrmona et al.
New publication on the role of #macrophages in shaping the tumor #microenvironment in #cancer ... leading to the exploration of #adipose tissue and it's impact on #innateimmunity and #adaptiveimmunity in #ovariancancer to the point where resistancr to […]
[Original post on mstdn.science]
Recruiting Hematology and Medical Oncology Faculty at Cleveland Clinic - Jame Abraham
@jameabraham.bsky.social @clevelandclinic.bsky.social
oncodaily.com/voices/jame-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Hematology #MedicalOncology #ClevelandClinic
A big welcome to our #MedicalOncology colleagues from National Cancer Institute of Ukraine 🇺🇦. Looking forward to working with you all this week and beyond!
@mcrcnews.bsky.social
@christieinstitute.bsky.social
Have you registered for the COACH-ED Dinner & Accredited Education Session?
In just 3 days we meet in San Francisco to shape the future of cancer cachexia care.
Register today: cancercachexiasociety.org/COACH-ED-Jan9.
#COACHED #COACHEDSanFran #CancerCachexia #MedicalOncology #SupportiveOncology
Will you be in San Francisco on January 9, 2026?
Register for the COACH-ED accredited session where experts break down why cancer cachexia matters and how it can be managed!
cancercachexiasociety.org/COACH-ED-Jan9.
#COACHED #COACHEDSanFran #CancerCachexia #MedicalOncology #SupportiveOncology
Dr. Eric Roeland, from Oregon Health & Science University, is one of our guest speakers at the COACH-ED Dinner & Educational Session. Register today: cancercachexiasociety.org/COACH-ED-Jan9 to hear his talk at this free dinner event!
#COACHED #COACHEDSanFran #CancerCachexia #MedicalOncology
A new study found that women with very early-stage DCIS who took tamoxifen alone had higher recurrence rates than expected.
youtu.be/BxuHU5Kb_pM
#DCIS #BreastCancer #LowRiskDCIS #BreastCancerResearch #Oncology #MedicalOncology #BreastCancerAwareness #CancerResearch #Tamoxifen
The program for the COACH-ED Dinner & Education Session is live!
Look through the agenda at www.cancercachexiasociety.org/san-francisc...
#COACHED #COACHEDSanFran #CancerCachexia #MedicalOncology #SupportiveOncology
Register now for COACH-Ed in San Franciso
Will you be in San Francisco on January 9, 2026?
We hope to see you at the COACH-ED Dinner & Education Session as experts break down why cachexia matters and how it can be managed. Register today:
cancercachexiasociety.org/COACH-ED-Jan9
#COACHED #COACHEDSanFran #CancerCachexia #MedicalOncology
Understanding Chemotherapy Treatment | Dr. Ranga Rao
#DrRangaRao #Chemotherapy #CancerTreatment #CancerFighters #Oncologist #ParasHospitalDelhi #MedicalOncology #india
🔗 Watch Full video:-https://youtube.com/shorts/4JXcWKAjkRo?feature=share
👉 Missed the #ESMOAcademy25 or want a refresher? Catch up now with expert insights, key takeaways & full session replays — exclusively on OncologyPRO.
🔗 buff.ly/cjTY2Qd
#OncologyPRO #MedicalOncology #ESMOEvents #CareerDevelopment
Capivasertib/Fulvestrant in patients with HR+, HER2-low or HER2-negative locally advanced or metastatic breast cancer
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#medicaloncology #combinationtherapy #targetedtherapy #oncosky #medsky #openaccess
Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#medicaloncology #oncosky #medsky #HCC #livercancer #cancertreatment #openaccess
Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#medicaloncology #oncosky #NETs #pancreaticcancer #medsky #openaccess
Happy to do teaching for a living.
#MedicalOncology #MedicalEducation
🚨 Now Hiring: Medical Oncologist – Community/Academic Position | New York Metro Area.
📩 Interested? Send your resume to recruiting@generationhealthsearch.com to start the conversation.
#OncologyJobs #MedicalOncology #PhysicianJobs #Academic #NowHiring #healthcare #Newyork #faculty #community
Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies
@tamedoncol.bsky.social
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#kidneycancer #targetedtherapy #immunotherapy #medicaloncology #oncology #oncsky #medsky #openaccess
Follow along for real-time updates from #ASCO25 and insights from the ground floor of the world’s leading oncology conference!
www.targetedonc.com/conference/a...
#OncologyInnovation #MedicalOncology #CancerResearch #PrecisionMedicine
📢 Are you a fourth- or fifth-year #MedicalStudent looking for insights into #MedicalOncology to help you make your choice of specialisation?
👉 Apply to attend the #ESMOCourse25 in #MedicalOncology.
🔗 buff.ly/fJFkyUw
Tonight at 7:30pm, #YaleCancerAnswers host Dr. Eric Winer and #lungcancer expert Dr. Roy Herbst celebrate 50 years of progress in #MedicalOncology, honoring the 50th Anniversary of @yalecancer.bsky.social.
🎧Listen live WNPR
🔃 Download Apple Podcasts
💻Watch on YouTube
#lcsm